A Phase II Nonrandomized Study of Oxaliplatin/Doxorubicin Combination Therapy in the Treatment of Recurrent Ovarian Cancer  by Pokataev, Ilya et al.
Original StudyA Phase II Nonrandomized Study of
Oxaliplatin/Doxorubicin Combination Therapy in
the Treatment of Recurrent Ovarian Cancer
Ilya Pokataev, Alexey Tryakin, Alexandra Tjulandina, Mikhail Fedyanin,
Sergei Tjulandin
Abstract
The study was aimed at evaluating oxaliplatin/doxorubicin combination therapy in recurrent ovarian cancer.
Patients with recurrent ovarian cancer in whom the platinum-free interval had been < 24 months received
doxorubicin/oxaliplatin. The median progression-free survival times in platinum-sensitive and platinum-
resistant cancer were 10.8 and 6.7 months, respectively. The combination of oxaliplatin/doxorubicin is an
active regimen in both platinum-sensitive and platinum-resistant ovarian cancer.
Introduction: This study was aimed at evaluating the efﬁcacy and tolerability of oxaliplatin/doxorubicin combination
therapy in patients with platinum-sensitive and platinum-resistant ovarian cancer. Materials and Methods: Patients
with recurrent ovarian cancer after 1 regimen of platinum-based chemotherapy received doxorubicin (50 mg/m2
intravenously) and oxaliplatin (130 mg/m2 intravenously) on day 1 every 3 weeks. The platinum-free interval was set to
be < 24 months. Results: A total of 33 patients were enrolled (21 platinum-resistant and 12 platinum-sensitive re-
lapses). The response rate in platinum-resistant ovarian cancer was lower than in platinum-sensitive disease (33.4%
vs. 54.5%), although the difference was not statistically signiﬁcant (P ¼ .59). The median progression-free survival
(PFS) and overall survival in the whole cohort were 7.4 and 24.3 months, respectively. PFS in platinum-sensitive
cancer was longer than in platinum-resistant cancer (10.8 vs. 6.7 months); however, this difference did not reach
statistical signiﬁcance (P ¼ .14). Conclusion: The combination of oxaliplatin/doxorubicin is an active regimen for
patients with platinum-sensitive and platinum-resistant recurrent ovarian cancer.
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Ovarian cancer is the leading cause of death among women with
gynecologic cancer in the world. The high mortality rate is related to
the late diagnosis of this disease: more than 70% of ovarian cancers
are diagnosed in stage III or IV. Standard treatment, including
maximum-effort cytoreductive surgery and platinum-based
chemotherapy, results in complete remission in most patients.
Unfortunately, almost all patients with advanced ovarian cancer
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http://dx.doi.org/10.1016/j.cogc.2014.06.002treatment of platinum-sensitive relapses includes a platinum com-
pound (cisplatin or carboplatin) combined with paclitaxel, gemci-
tabine, pegylated liposomal doxorubicin, or another agent.
Treatment of platinum-resistant relapses usually includes mono-
therapy with any of the potentially active nonplatinum drugs, for
example, pegylated liposomal doxorubicin, topotecan, weekly
paclitaxel, gemcitabine, or oral etoposide.1 Oxaliplatin is currently
an uncommon drug in the treatment of recurrent ovarian cancer.
The promising advantage of oxaliplatin is no complete cross-
resistance between this drug and other platinum agents in solid
tumors.2 Therefore, oxaliplatin showed promising efﬁcacy in both
platinum-sensitive and platinum-resistant ovarian cancer in several
phase II clinical trials.3-8 The objective response rate for different
oxaliplatin-based regimens, including combinations with pegylated
liposomal doxorubicin, ranges from 29% to 67%.9-21 Availability of
pegylated liposomal doxorubicin is limited owing to its high cost.
On the other hand, the efﬁcacy of conventional doxorubicin is notClinical Ovarian and Other Gynecologic Cancer December 2013 - 11
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12 -inferior to that of pegylated liposomal doxorubicin. The only ran-
domized study that compared the efﬁcacy of the 2 drugs was con-
ducted in metastatic breast cancer. It showed similar efﬁcacy of
conventional doxorubicin and pegylated liposomal doxorubicin but
different safety proﬁles.22
Therefore, the aim of the present phase II nonrandomized study
was to determine the efﬁcacy and tolerability of oxaliplatin/doxo-
rubicin combination therapy in patients with recurrent ovarian
cancer. This study focused mostly on patients with platinum-
resistant cancer, relying on the concept of no complete cross-
resistance between oxaliplatin and carboplatin. However, the
study also included patients with platinum-sensitive cancer who had
had a platinum-free interval (PFI) of < 24 months. It was supposed
that these patients could beneﬁt from the change of a platinum
compound to overcome potential resistance. Patients with very
platinum-sensitive ovarian cancer (PFI > 24 months) were
excluded, because generally these patients get maximum advantage
from reintroduction of a previous platinum-based regimen.23
Materials and Methods
Study Design
This is a single-institution prospective nonrandomized phase II
study evaluating oxaliplatin/doxorubicin combination therapy in
patients with platinum-sensitive or platinum-resistant ovarian cancer.
The study protocol and the related consent formwere approved by the
Ethics Committee of the authors’ institution. All patients enrolled in
the study received doxorubicin 50 mg/m2 intravenously over 15
minutes followed by oxaliplatin 130 mg/m2 intravenously over 120
minutes on day 1 every 3weeks. All patients were expected to receive 6
cycles followed by surveillance every 8weeks until disease progression.
The next cycle of chemotherapy was not administered unless the
absolute neutrophil count was > 1500 cells/mL and the platelet
count was > 100,000 cells/mL. Support with granulocyte colony-
stimulating factors or erythropoiesis-stimulating agents was allowed
according to the American Society of Clinical Oncology guide-
lines.24,25 In case of treatment-related adverse events leading to a
cycle delay of > 4 days, dose reductions of both drugs were allowed.
Assessment of Response and Evaluation of Toxicity
To evaluate the disease sites, all patients underwent abdominal
ultrasonography or computed tomography scan and serum CA-125
(cancer antigen 125 [MUC16]) level measurement within 2 weeks
before cycle 1. Disease assessment was repeated using the same
modalities after cycles 2 and 4 and at the end of the treatment. In
patients without signs of disease progression at the end of the
treatment, disease assessment was repeated every 8 weeks until
disease progression. The clinical response was deﬁned according to
World Health Organization (WHO) criteria.26,27 Patients with
complete response (CR) according to the WHO criteria in whom
CA-125 levels had come to normal were considered to have a
complete clinical response. Patients with CR according to the
WHO criteria in whom CA-125 levels had not normalized were
considered to have a partial clinical response. Patients with pro-
gressive disease according to the WHO criteria or with a rise in
serum CA-125 levels by > 50% were considered to have disease
progression.Clinical Ovarian and Other Gynecologic Cancer December 2013Safety was evaluated in accordance with the US National Cancer
Institute Common Terminology Criteria for Adverse Events
(CTCAE) version 3.0. Biochemical parameters were measured on
day 1 of each treatment cycle; hematologic parameters were
measured weekly until the end of the treatment.
Eligibility Criteria
Eligible patients had advanced ovarian cancer previously treated
with only 1 platinum-based chemotherapy regimen. The goal of the
limitation of a previous anticancer therapy to only 1 regimen was
the intention to reach homogeneity of the population for correct
interpretation of long-term results (progression-free survival [PFS]
and overall survival [OS]). Patients with increased serum CA-125
levels as the only sign of disease progression were not included.
All patients had to be older than 18 years and had to have a per-
formance status of either 0, 1, or 2 according to ECOG (Eastern
Cooperative Oncology Group) criteria. Morphologic conﬁrmation
of ovarian cancer was required. PFI had to be < 24 months since
the last platinum administration. PFI was deﬁned as the time period
from the last platinum administration to the disease progression
(according to CA-125 level, objective methods of assessment, or
both). Patients with PFI < 6 months were considered platinum-
resistant. Patients with PFI  6 months were considered
platinum-sensitive. Patients with platelet counts < 100,000 cells/
mL, absolute neutrophil counts < 1500 cells/mL, hemoglobin
levels < 9 g/dL, inadequate liver function (total bilirubin > 30
mmol/L) or renal function (serum creatinine > 130 mmol/L), or
signiﬁcant cardiovascular diseases with left ventricular ejection
fraction < 60% were excluded. Severe concomitant diseases, sensory
neuropathy > grade 1, or other malignancies were also criteria for
patient exclusion.
Statistical Considerations
The primary endpoint was PFS calculated from the start of
investigational therapy to disease progression or the last date of
patient contact. Secondary endpoints were OS, objective response
rate, and safety. The authors expected to enroll not less than 60% of
patients with PFI < 6 months after ﬁrst-line platinum-based
chemotherapy. Analysis of the database of the authors’ department
at the N.N. Blokhin Russian Cancer Research Center found that 6-
month PFS in this patient cohort was 30%. A 1-stage design was
used. With the use of a new regimen, the authors expected to in-
crease 6-month PFS to 55%. To test this hypothesis, 32 patients
were needed for accrual with a ¼ .1, power ¼ .9, and a 10% drop-
out rate. All calculations were done using Statistica software (version
8.0; StatSoft Inc).
Results
From January 2009 to June 2012, 33 patients received treatment
in this clinical trial. Patient characteristics are shown in Table 1.
Most of the patients had platinum-resistant relapses (63.6%), serous
histology (81.9%), and ECOG performance status of 0 or 1 (97%).
The time intervals from the last platinum administration to the start
of investigational therapy for the entire study group and for patients
with platinum-resistant relapses were 6.2 and 5.0 months,
respectively.
Figure 1 Progression-Free Survival and Overall Survival of
the Whole Study Group
Table 1 Patients’ Baseline Characteristics (n [ 33)
Characteristic Value
Age (years)
Median 54
Range 16-74
ECOG Performance Status, n (%)
0 13 (39.4%)
1 19 (57.6%)
2 1 (3.0%)
Tumor Histology, n (%)
Serous 27 (81.9%)
Clear cell 1 (3.0%)
Mucinous 1 (3.0%)
Adenocarcinoma, unspeciﬁed 4 (12.1%)
CA-125 Level Before Chemotherapy, IU/mL
Median 274
Range 21-3385
Patients With Prior Taxane-Based Therapy, n (%) 27 (81.9%)
Platinum-Free Interval
< 6 mo 21 (63.6%)
6-12 mo 6 (18.2%)
> 12 mo 6 (18.2%)
Time From the Last Platinum Administration to the Start of
Investigational Therapy in the Whole Cohort (mo)
Median 6.2
Range 0.4-46.9
Time From the Last Platinum Administration to the Start of
Investigational Therapy in the Platinum-Resistant Cohort (mo)
Median 5.0
Range 0.4-15.8
Abbreviations: CA-125 ¼ cancer antigen 125 (MUC16); ECOG ¼ Eastern Cooperative Oncology
Group.
Ilya Pokataev et alObjective response could be measured in 29 of 33 patients. The
other 4 patients had only unmeasurable lesions. The response rates
for the whole group and depending on platinum sensitivity are
shown in Table 2.
The response rate for the entire study group was 41.4% (12 of
29), including 7 complete (24.2%) and 5 partial (17.2%) responses.
The response rate in platinum-resistant ovarian cancer was lowerTable 2 Objective Response Rate With Oxaliplatin/
Doxorubicin Combination Therapy
Response
Type All Patients
Patients With
PFI < 6 mo
Patients With
PFI > 6 mo
Complete
Response
7 (24.2%) 3 (16.7%) 4 (36.3%)
Partial Response 5 (17.2%) 3 (16.7%) 2 (18.2%)
Stable Disease 12 (41.4%) 8 (44.4%) 4 (36.4%)
Progressive
Disease
5 (17.2%) 4 (22.2%) 1 (9.1%)
Total 29 (100%) 18 (100%) 11(100%)
Abbreviation: PFI ¼ platinum-free interval.than in platinum-sensitive disease (54.5% vs. 33.4%), but the dif-
ference was not statistically signiﬁcant (P ¼ .59).
The median follow-up time was 17.0 months (range, 4.5-47.3);
47% of patients had died by the time of the present analysis. The
median PFS in the whole cohort was 7.4 months (Figure 1). The
6-month and 1-year PFS values were 65.6% and 28.1%, respec-
tively. The median OS was 24.3 months.
There was a difference in PFS between platinum-sensitive and
platinum-resistant cancers (10.8 vs. 6.7 months), but it did not
reach statistical signiﬁcance (P ¼ .14) (Figure 2A). OS was higher in
platinum-sensitive disease (30.4 vs. 18.2 months), which was sta-
tistically signiﬁcant (P ¼ .02) (see Figure 2B).
The median number of delivered cycles was 6 (range, 2-8). There
were no deaths during the study procedures. One patient was
withdrawn after 2 cycles owing to development of acute (M4)
leukemia. The most often reported adverse events of chemotherapy
are shown in Table 3.
Oxaliplatin and doxorubicin dose reductions were registered in
43.8% and 56.0% of patients, respectively. The main reason for
dose reductions was grade 3 or 4 neutropenia, which was reported in
27.5% of cycles. Febrile neutropenia occurred in 2.6% of cycles.
Grade 3 or 4 thrombocytopenia occurred in 5.5% of cycles. Despite
the use of serotonin receptor 5-HT3 antagonists and dexamethasone
prophylaxis, grade 3 or 4 nausea was registered in 6.3% of cycles.
Grade 3 or 4 asthenia occurred in 7.3% of cycles. In 9.4% of cases
grade 3 neurotoxicity was reported. Other adverse events were mild
or moderate in most cases. There were no symptomatic or asymp-
tomatic cardiotoxic events reported in this study.
Discussion
The gold standard chemotherapy for recurrent ovarian cancer has
yet to be determined. Platinum-sensitive recurrences require rein-
troduction of a platinum compound combined with another
potentially active cytotoxic agent. In most cases, platinum-resistant
recurrences are managed by nonplatinum compounds delivered
as monotherapy. However, there is no preferred chemotherapyAbbreviations: OS ¼ overall survival; PFS ¼ progression-free survival.
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Figure 2 Progression-Free Survival (A) and Overall Survival (B) in Platinum-Sensitive and Platinum-Resistant Cohorts
Abbreviation: Pt ¼ platinum-based drug.
Table 3 Safety of Oxaliplatin/Doxorubicin Chemotherapy
Adverse Event Any Grade Grade 3 or 4
Neutropeniaa 72.3% 27.5%
Febrile neutropeniaa 2.6% 2.6%
Thrombocytopeniaa 12.5% 5.5%
Anemiab 11.7% 0%
Neurotoxicityb 75.0% 9.4%
Nauseaa 71.3% 6.3%
Astheniaa 54.5% 7.3%
AST/ALT Elevationb 29.0% 0%
Diarrheaa 3.1% 0%
Stomatitisa 2.1% 0%
Cardiotoxicityb 0% 0%
Abbreviation: AST/ALT ¼ aspartate transaminaseealanine transaminase ratio.
aCalculated to number of cycles.
bCalculated to number of patients.
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14 -regimen, as no regimen has shown greater clinical beneﬁt compared
with any other in both platinum-sensitive and platinum-resistant
disease.1
The present authors chose an oxaliplatin-based regimen in this
clinical trial because (1) oxaliplatin, as a platinum compound, is
applicable in the treatment of platinum-sensitive recurrences and
because (2) tumors resistant to other platinum compounds do not
show complete resistance to oxaliplatin,2 so oxaliplatin can be
used in platinum-resistant tumors as well. The inclusion/exclu-
sion criteria allowed enrollment of patients with platinum-
sensitive tumors with PFI < 24 months. The authors believe
that optimal chemotherapy in recurrent ovarian cancer with PFI
> 24 months should be based on carboplatin or cisplatin.
Carboplatin- or cisplatin-based chemotherapy in platinum-
sensitive tumors with PFI of 6 to 24 months has shown moder-
ate efﬁcacy, with median PFS < 10 months and development of
platinum-resistant recurrences in > 50% of cases.28 Therefore, it
is important to ﬁnd different approaches to overcome platinum
resistance in such cases.
A large number of trials dedicated to the problem of overcoming
platinum resistance by the use of different novel chemotherapy
regimens have been performed to date. Some of these trials were
based on novel ways of administration of platinum compounds.
Investigators from London Imperial College reported on dose-dense
and dose-intensive chemotherapy with weekly carboplatin (area
under the curve ¼ 3 mg/mL,min) and paclitaxel (70 mg/m2) in
platinum-resistant ovarian cancer. This approach showed promising
results, with a response rate of 60% and a median PFS of
7.9 months. Median OS was 13 months.29 Ledermann et al
(2010)30 evaluated the efﬁcacy of carboplatin/gemcitabine combi-
nation therapy in platinum-resistant disease. They found that
gemcitabine inhibited reparation of interstrand links in DNA
caused by carboplatin. The overall response rate in this study was
29%, and the median PFS and OS were 6.9 and 11.7 months,
respectively.Clinical Ovarian and Other Gynecologic Cancer December 2013In the present study, in the cohort of platinum-resistant tumors,
the response rate was 33.4%, and the median PFS and OS were
6.7 and 18.2 months, respectively. These results are comparable
with the outcomes of the aforementioned trials. Of 21 patients
with platinum-resistant ovarian cancer, 5 (23.8%) had a PFI after
the second-line oxaliplatin/doxorubicin chemotherapy longer than
6 months. These data support the hypothesis of incomplete cross-
resistance between oxaliplatin and other platinum agents in solid
tumors. The OS rate in the present study was higher than in the
aforementioned trials because all patients received investigational
therapy in the second-line setting, and a lot of potentially effective
drugs were available for them later.
All patients in this study did not have an artiﬁcial prolongation
of the PFI after the previous platinum-based chemotherapy by
administration of nonplatinum regimens. However, this study was
limited to the patients with symptomatic recurrences; the patients
with elevation of the CA-125 level as the only sign of recurrence
Ilya Pokataev et alwere not included. Therefore, the median time from the last plat-
inum administration to the start of investigational therapy in the
platinum-resistant cohort was 5.0 months (range, 0.4-15.8). The
study analyzed how the length of this interval affected the efﬁcacy of
chemotherapy, and it was found that the objective response rate
(P ¼ .1) and PFS (P ¼ .76) did not correlate with the length of this
interval in the platinum-resistant cohort.
Patients with platinum-sensitive ovarian cancer had 54.5% of
the objective responses, and the median PFS was 10.8 months
(range, 0.7-20.2). Only 2 patients developed platinum-resistant
recurrences after the second-line oxaliplatin/doxorubicin chemo-
therapy. Such remarkable results support the authors’ opinion that
oxaliplatin/doxorubicin combination therapy is a useful treatment
option for platinum-sensitive tumors. These results are comparable
with the published data showing that second-line chemotherapy
with carboplatin plus gemcitabine, carboplatin plus pegylated
liposomal doxorubicin, or carboplatin plus paclitaxel resulted in a
median PFS of 8.4 to 11.3 months in platinum-sensitive ovarian
cancer.31,32
The toxicity of the oxaliplatin/doxorubicin combination appeared
manageable. Unfortunately, the frequency of dose reductions was
high. Doses of oxaliplatin/doxorubicin were reduced in 43.8% and
56% of cases, respectively. The reason for dose reductions in most
cases was grade 3 or 4 neutropenia. Secondary prophylaxis with
granulocyte colony-stimulating factor in patients with severe neu-
tropenia could decrease the rate of dose reductions. The other grade
3 or 4 toxicities included thrombocytopenia, asthenia, and nausea,
which occurred in 5.5%, 7.3%, and 6.3% of cycles, respectively.
Neurotoxicity was diagnosed in 9.4% of patients. There were no
treatment-related deaths. The present investigational regimen is
cost-effective owing to the moderate price of oxaliplatin and
doxorubicin. Another advantage of this regimen is that patients
require hospital visits only once every 3 weeks. Therefore, the au-
thors propose this regimen as a treatment of choice for recurrent
ovarian cancer in both developing and developed countries.
Conclusion
The novel chemotherapy regimen for platinum-sensitive and
platinum-resistant ovarian cancer that includes the combination of
oxaliplatin/doxorubicin showed promising results in a small group
of patients. These results need conﬁrmation in a larger clinical trial.
Clinical Practice Points
 There are no gold standards of chemotherapy for both platinum-
sensitive and platinum-resistant recurrent ovarian cancer. Oxa-
liplatin and doxorubicin seem to be active drugs in recurrent
ovarian cancer but nowadays are rarely used for this indication.
 This study found that the investigational combination of oxali-
platin/doxorubicin is active in both platinum-sensitive and
platinum-resistant ovarian cancer. The objective response rate
and PFS in the platinum-resistant cohort were comparable with
the best results published in the literature.
 The toxicity proﬁle of the oxaliplatin/doxorubicin combination
appeared manageable. This regimen is cost-effective owing to the
acceptable price of oxaliplatin and doxorubicin. Another
advantage of this regimen is the need for hospital visits only once
every 3 weeks.Acknowledgments
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